Xiuli Guo

Dr. Xiuli Guo


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in Journal of Controlled Release
Verified
Journal Article
Closed access
XYXiao-Xia Yang
Xiao-Xia Yang
CSChao Sun
Chao Sun
LWLei Wang
Lei Wang
XGXiuli Guo
Xiuli Guo

27 April 2016 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
HZHui-Hui Zhang
Hui-Hui Zhang
XGXiuli Guo
Xiuli Guo

26 March 2016 in Protein & Cell
Verified
Journal Article
Open access
PDF file
ZCZhan-Qi Cao
Zhan-Qi Cao
XGXiuli Guo
Xiuli Guo
Galectin-4, a tandem repeat member of the β-galactoside-binding proteins, possesses two carbohydrate-recognition domains (CRD) in a single peptide chain. This lectin is mostly expressed in epithelial cells of the intestinal tract and secreted to the extracellular. The two domains have 40% similarity in amino acid sequence, but distinctly binding to various ligands. Just because the two domains bind to different ligands simultaneously, galectin-4 can be a crosslinker and crucial regulator in a large number of biological processes. Recent evidence shows that galectin-4 plays an important role in lipid raft stabilization, protein apical trafficking, cell adhesion, wound healing, intestinal inflammation, tumor progression, etc. This article reviews the physiological and pathological features of galectin-4 and its important role in such processes.

19 August 2017 in Molecular Carcinogenesis
Verified
Journal Article
Closed access
PDF file
HZHui‐Hui Zhang
Hui‐Hui Zhang
YZYing Zhang
Ying Zhang
YCYan‐Na Cheng
Yan‐Na Cheng
FGFu‐Lian Gong
Fu‐Lian Gong
ZCZhan‐Qi Cao
Zhan‐Qi Cao
XGXiuli Guo
Xiuli Guo

1 December 2017 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
YZYing Zhang
Ying Zhang
SYShao-Hui Yang
Shao-Hui Yang
XGXiuli Guo
Xiuli Guo

1 December 2009 in Current Neuropharmacology
Verified
Journal Article
Open access
PDF file
XDXue Dong
Xue Dong
YSYu-Ning Song
Yu-Ning Song
WLWei-Guo Liu
Wei-Guo Liu
XGXiuli Guo
Xiuli Guo
Matrix metalloproteinase-9 (MMP-9) which is a member of matrix metalloproteinases family that normally remodel the extracellular matrix, has been shown to play an important role in both animal models of cerebral ischemia and human stroke. The expression of MMP-9 is elevated after cerebral ischemia which is involved in accelerating matrix degradation, disrupting the blood-brain barrier, increasing the infarct size and relating to hemorrhagic transformation. Recently, many drugs, such as tetracycline derivatives, cyclooxygenase inhibitors, ACEI inhibitors and AT1 receptor blockers, etc., have been found to attenuate the elevated expression levels of MMP-9 after ischemia and to reduce the damage of cerebral ischemic. This article reviews the physiological features of MMP-9 and its important role in the genesis, propagation, and therapeutics of cerebral ischemic diseases.